secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001493152-24-007784
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte signs exclusive patent license with NINDS and NCI for LB-100 combination therapy
--------------------------------------------------------------------------------

- Exclusive license covers NIH IP co-developed under CRADA; field includes checkpoint inhibitors, immunotherapy, radiation.
- Upfront license issue royalty $50,000; annual minimum $30,000; earned royalties 2% on net sales (floor 1%).
- Benchmark payments up to $1,225,000 tied to milestones; first Phase 2 patient dosing due October 2024.
- LB-100 is first-in-class PP2A inhibitor; ongoing Phase 1b/2 OCCC trial with dostarlimab and Phase 1b SCLC trial with atezolizumab.
- CEO called the collaboration a significant milestone to advance LB-100 as potentiator of cancer immunotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224007784/0001493152-24-007784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224007784/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-007784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer